Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin for Endothelial Dysfunction in Sickle Cell Disease
NCT01732718Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atorvastatin in sickle cell disease (SCD) and sickle cell nephropathy (SCN) (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Change From Baseline to Week 6 in Endothelial Function. Started Sep 2013; status: completed.
02
Drugs
atorvastatin
03
Conditions
sickle cell disease (SCD)sickle cell nephropathy (SCN)
Beyond the preview
Go deeper on NCT01732718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732718.